Jeffrey Wiezorek
Fondateur chez Appia Bio, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Robert Bradway | M | 61 | 18 ans | |
David Baltimore | M | 86 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Jeenjoo Kang | M | 40 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Ronald Sugar | M | 75 | 14 ans | |
Tyler Jacks | M | 63 | 12 ans | |
Greg Garland | M | 66 | 11 ans | |
Esteban Santos | M | 56 | 17 ans | |
Lili Yang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Edmund Kim | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Pin Wang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 ans |
Margo Roberts | M | 69 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 2 ans |
Daqing Cai | M | 59 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
David Moskowitz | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
Francisco Gimenez | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
Mark J. Taisey | M | - | 10 ans | |
Rachna Khosla | F | - | 11 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jeffrey Wiezorek
- Réseau Personnel